drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB06791 | DB09351 | 1,446 | 722 | [
"DDInter1021",
"DDInter1048"
] | Lanreotide | Levobetaxolol (ophthalmic) | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | (S)-betaxolol is the (S)-enantiomer of betaxolol. It is an enantiomer of a (R)-betaxolol. | Moderate | 1 | [
[
[
1446,
24,
722
]
],
[
[
1446,
63,
699
],
[
699,
62,
27
],
[
27,
23,
722
]
],
[
[
1446,
63,
699
],
[
699,
24,
1276
],
[
1276,
63,
... | [
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
],
[
... | Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol may cause a minor interaction that can limit clinical effects when taken with Glucagon and Glucagon may ... |
DB01115 | DB12941 | 336 | 466 | [
"DDInter1291",
"DDInter481"
] | Nifedipine | Darolutamide | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Minor | 0 | [
[
[
336,
23,
466
]
],
[
[
336,
24,
1446
],
[
1446,
23,
466
]
],
[
[
336,
63,
600
],
[
600,
23,
466
]
],
[
[
336,
40,
376
],
[
376,
2... | [
[
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
],
[
... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and Lanreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluco... |
DB06589 | DB09118 | 1,250 | 1,580 | [
"DDInter1400",
"DDInter1711"
] | Pazopanib | Stiripentol | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
1250,
24,
1580
]
],
[
[
1250,
24,
466
],
[
466,
62,
1580
]
],
[
[
1250,
24,
283
],
[
283,
63,
1580
]
],
[
[
1250,
63,
473
],
[
473,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Stiripentol
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedra... |
DB08820 | DB09039 | 1,478 | 1,670 | [
"DDInter997",
"DDInter629"
] | Ivacaftor | Eliglustat | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
1478,
24,
1670
]
],
[
[
1478,
62,
479
],
[
479,
23,
1670
]
],
[
[
1478,
63,
211
],
[
211,
23,
1670
]
],
[
[
1478,
23,
1135
],
[
1135,
... | [
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"... | Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine m... |
DB00604 | DB06288 | 1,425 | 607 | [
"DDInter385",
"DDInter77"
] | Cisapride | Amisulpride | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Major | 2 | [
[
[
1425,
25,
607
]
],
[
[
1425,
6,
6962
],
[
6962,
45,
607
]
],
[
[
1425,
23,
112
],
[
112,
23,
607
]
],
[
[
1425,
24,
1559
],
[
1559,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"HTR2B"
],
[
"HTR2B",
"{u} (Gene) is bound by {v} (Compound)",
"Amisulprid... | Cisapride (Compound) binds HTR2B (Gene) and HTR2B (Gene) is bound by Amisulpride (Compound)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Amisulpride
Cisapride may caus... |
DB09079 | DB11581 | 1,496 | 1,456 | [
"DDInter1296",
"DDInter1926"
] | Nintedanib | Venetoclax | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
1496,
24,
1456
]
],
[
[
1496,
24,
241
],
[
241,
63,
1456
]
],
[
[
1496,
63,
804
],
[
804,
24,
1456
]
],
[
[
1496,
24,
98
],
[
98,
... | [
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
],
[
... | Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone and ... |
DB09122 | DB14730 | 1,613 | 1,412 | [
"DDInter1409",
"DDInter264"
] | Peginterferon beta-1a | Calaspargase pegol | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1613,
24,
1412
]
],
[
[
1613,
63,
250
],
[
250,
24,
1412
]
],
[
[
1613,
24,
159
],
[
159,
24,
1412
]
],
[
[
1613,
64,
593
],
[
593,
... | [
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases whe... |
DB01149 | DB06697 | 851 | 436 | [
"DDInter1274",
"DDInter121"
] | Nefazodone | Artemether | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</... | Major | 2 | [
[
[
851,
25,
436
]
],
[
[
851,
6,
12523
],
[
12523,
45,
436
]
],
[
[
851,
25,
283
],
[
283,
63,
436
]
],
[
[
851,
24,
1220
],
[
1220,
... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Artemether"
]
],
[
[
"Nefazodone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Artemet... | Nefazodone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Artemether (Compound)
Nefazodone may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Artemether
Nefazodone may cause a moderate i... |
DB00092 | DB00791 | 58 | 132 | [
"DDInter40",
"DDInter1902"
] | Alefacept | Uracil mustard | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | Moderate | 1 | [
[
[
58,
24,
132
]
],
[
[
58,
24,
970
],
[
970,
40,
132
]
],
[
[
58,
24,
1430
],
[
1430,
63,
132
]
],
[
[
58,
23,
1461
],
[
1461,
24,... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Uracil mustard"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
],
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil (Compound) resembles Uracil mustard (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction ... |
DB00363 | DB04865 | 695 | 4 | [
"DDInter419",
"DDInter1335"
] | Clozapine | Omacetaxine mepesuccinate | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
695,
25,
4
]
],
[
[
695,
6,
9842
],
[
9842,
46,
4
]
],
[
[
695,
18,
2976
],
[
2976,
57,
4
]
],
[
[
695,
64,
1394
],
[
1394,
24,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A1"
],
[
"CYP1A1",
"{u} (Gene) is upregulated by {v} (Compoun... | Clozapine (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Clozapine (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Clozapine may lead to a major life threatening interaction when taken with Rituximab... |
DB00773 | DB00776 | 896 | 1,335 | [
"DDInter702",
"DDInter1360"
] | Etoposide | Oxcarbazepine | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Moderate | 1 | [
[
[
896,
24,
1335
]
],
[
[
896,
63,
126
],
[
126,
1,
1335
]
],
[
[
896,
62,
307
],
[
307,
1,
1335
]
],
[
[
896,
6,
7524
],
[
7524,
4... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Oxcarbazepine (Compound)
Etoposide may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Oxcarbazepine (Compound)
Etop... |
DB00186 | DB01619 | 905 | 830 | [
"DDInter1092",
"DDInter1441"
] | Lorazepam | Phenindamine | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
905,
24,
830
]
],
[
[
905,
24,
1219
],
[
1219,
40,
830
]
],
[
[
905,
24,
13
],
[
13,
24,
830
]
],
[
[
905,
24,
104
],
[
104,
1,
... | [
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
... | Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine (Compound) resembles Phenindamine (Compound)
Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that... |
DB00031 | DB00081 | 20 | 273 | [
"DDInter1764",
"DDInter1838"
] | Tenecteplase | Tositumomab | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Major | 2 | [
[
[
20,
25,
273
]
],
[
[
20,
23,
539
],
[
539,
62,
273
]
],
[
[
20,
24,
109
],
[
109,
63,
273
]
],
[
[
20,
25,
1618
],
[
1618,
64,
... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tositumomab"
]
],
[
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum"... | Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Tositumomab
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetin... |
DB00207 | DB08881 | 1,570 | 868 | [
"DDInter157",
"DDInter1925"
] | Azithromycin | Vemurafenib | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
1570,
25,
868
]
],
[
[
1570,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1570,
7,
7638
],
[
7638,
46,
868
]
],
[
[
1570,
18,
4187
],
[
4187,
... | [
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Azithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ve... | Azithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Azithromycin (Compound) upregulates DENND2D (Gene) and DENND2D (Gene) is upregulated by Vemurafenib (Compound)
Azithromycin (Compound) downregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is upregulated by Vemurafenib (Compoun... |
DB00526 | DB01005 | 1,555 | 995 | [
"DDInter1355",
"DDInter894"
] | Oxaliplatin | Hydroxyurea | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Moderate | 1 | [
[
[
1555,
24,
995
]
],
[
[
1555,
25,
945
],
[
945,
62,
995
]
],
[
[
1555,
64,
1176
],
[
1176,
23,
995
]
],
[
[
1555,
24,
872
],
[
872,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparf... | Oxaliplatin may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Hydroxyurea
Oxaliplatin may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may cause a mino... |
DB01050 | DB04865 | 848 | 4 | [
"DDInter900",
"DDInter1335"
] | Ibuprofen | Omacetaxine mepesuccinate | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
848,
25,
4
]
],
[
[
848,
6,
7720
],
[
7720,
46,
4
]
],
[
[
848,
40,
1307
],
[
1307,
24,
4
]
],
[
[
848,
63,
1645
],
[
1645,
24,
... | [
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Ibuprofen",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)... | Ibuprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Ibuprofen (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Ibuprofen may cause a moderate inter... |
DB09054 | DB14811 | 384 | 385 | [
"DDInter905",
"DDInter979"
] | Idelalisib | Isatuximab | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Moderate | 1 | [
[
[
384,
24,
385
]
],
[
[
384,
25,
1362
],
[
1362,
24,
385
]
],
[
[
384,
63,
328
],
[
328,
24,
385
]
],
[
[
384,
64,
134
],
[
134,
2... | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
... | Idelalisib may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may ca... |
DB00011 | DB08904 | 1,451 | 375 | [
"DDInter944",
"DDInter342"
] | Interferon alfa-n1 | Certolizumab pegol | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
1451,
24,
375
]
],
[
[
1451,
24,
231
],
[
231,
24,
375
]
],
[
[
1451,
24,
1434
],
[
1434,
63,
375
]
],
[
[
1451,
63,
491
],
[
491,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sta... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00745 | DB09291 | 307 | 741 | [
"DDInter1236",
"DDInter1615"
] | Modafinil | Rolapitant | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
307,
24,
741
]
],
[
[
307,
23,
1135
],
[
1135,
23,
741
]
],
[
[
307,
24,
159
],
[
159,
63,
741
]
],
[
[
307,
23,
973
],
[
973,
2... | [
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"... | Modafinil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectin... |
DB06605 | DB06674 | 1,409 | 908 | [
"DDInter108",
"DDInter837"
] | Apixaban | Golimumab | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
1409,
24,
908
]
],
[
[
1409,
63,
1461
],
[
1461,
23,
908
]
],
[
[
1409,
63,
336
],
[
336,
24,
908
]
],
[
[
1409,
64,
697
],
[
697,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"V... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may ... |
DB09054 | DB10583 | 384 | 949 | [
"DDInter905",
"DDInter415"
] | Idelalisib | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
384,
24,
949
]
],
[
[
384,
63,
550
],
[
550,
24,
949
]
],
[
[
384,
64,
1377
],
[
1377,
24,
949
]
],
[
[
384,
25,
1259
],
[
1259,
... | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when t... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Idelalisib may lead to a major life threatening interaction ... |
DB08912 | DB09039 | 1,040 | 1,670 | [
"DDInter462",
"DDInter629"
] | Dabrafenib | Eliglustat | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
1040,
24,
1670
]
],
[
[
1040,
63,
479
],
[
479,
23,
1670
]
],
[
[
1040,
24,
1135
],
[
1135,
62,
1670
]
],
[
[
1040,
63,
1409
],
[
1409... | [
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol m... |
DB09020 | DB11837 | 28 | 1,297 | [
"DDInter212",
"DDInter1351"
] | Bisacodyl | Osilodrostat | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
28,
24,
1297
]
],
[
[
28,
63,
623
],
[
623,
24,
1297
]
],
[
[
28,
24,
971
],
[
971,
63,
1297
]
],
[
[
28,
24,
286
],
[
286,
24,
... | [
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
... | Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilt... |
DB00570 | DB00978 | 147 | 739 | [
"DDInter1936",
"DDInter1084"
] | Vinblastine | Lomefloxacin | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Minor | 0 | [
[
[
147,
23,
739
]
],
[
[
147,
23,
945
],
[
945,
40,
739
]
],
[
[
147,
62,
1176
],
[
1176,
1,
739
]
],
[
[
147,
62,
1467
],
[
1467,
... | [
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
[
... | Vinblastine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (... |
DB00159 | DB12500 | 940 | 283 | [
"DDInter903",
"DDInter714"
] | Icosapent | Fedratinib | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conve... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
940,
24,
283
]
],
[
[
940,
24,
885
],
[
885,
24,
283
]
],
[
[
940,
24,
1564
],
[
1564,
25,
283
]
],
[
[
940,
63,
1578
],
[
1578,
... | [
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
... | Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide and Def... |
DB00783 | DB09098 | 1,438 | 98 | [
"DDInter679",
"DDInter1700"
] | Estradiol | Somatrem | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1438,
24,
98
]
],
[
[
1438,
24,
159
],
[
159,
63,
98
]
],
[
[
1438,
63,
1573
],
[
1573,
24,
98
]
],
[
[
1438,
24,
609
],
[
609,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Pred... |
DB12500 | DB13007 | 283 | 1,060 | [
"DDInter714",
"DDInter642"
] | Fedratinib | Enfortumab vedotin | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
283,
24,
1060
]
],
[
[
283,
64,
129
],
[
129,
23,
1060
]
],
[
[
283,
62,
1593
],
[
1593,
24,
1060
]
],
[
[
283,
63,
600
],
[
600,
... | [
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"... | Fedratinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib and Crizotinib ma... |
DB00376 | DB00836 | 1,105 | 543 | [
"DDInter1870",
"DDInter1088"
] | Trihexyphenidyl | Loperamide | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
1105,
24,
543
]
],
[
[
1105,
24,
649
],
[
649,
1,
543
]
],
[
[
1105,
24,
262
],
[
262,
24,
543
]
],
[
[
1105,
1,
11268
],
[
11268,
... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]... | Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Loperamide (Compound)
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction th... |
DB01246 | DB01267 | 820 | 519 | [
"DDInter45",
"DDInter1381"
] | Alimemazine | Paliperidone | A phenothiazine derivative that is used as an antipruritic. | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
820,
24,
519
]
],
[
[
820,
63,
1664
],
[
1664,
1,
519
]
],
[
[
820,
25,
924
],
[
924,
1,
519
]
],
[
[
820,
6,
10104
],
[
10104,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Alimemazine may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound)
Alime... |
DB09291 | DB11581 | 741 | 1,456 | [
"DDInter1615",
"DDInter1926"
] | Rolapitant | Venetoclax | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
741,
25,
1456
]
],
[
[
741,
62,
1135
],
[
1135,
23,
1456
]
],
[
[
741,
63,
536
],
[
536,
24,
1456
]
],
[
[
741,
25,
230
],
[
230,
... | [
[
[
"Rolapitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Rolapitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Rolapitant may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbit... |
DB01087 | DB11978 | 1,520 | 124 | [
"DDInter1520",
"DDInter822"
] | Primaquine | Glasdegib | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1520,
24,
124
]
],
[
[
1520,
62,
1247
],
[
1247,
23,
124
]
],
[
[
1520,
24,
1079
],
[
1079,
24,
124
]
],
[
[
1520,
24,
1032
],
[
1032,... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[... | Primaquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and... |
DB00394 | DB11124 | 218 | 209 | [
"DDInter168",
"DDInter1560"
] | Beclomethasone dipropionate | Racepinephrine | Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to [dexamethasone]. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Bec... | Racepinephrine is a racemic mixture consisting of d- and l- enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest and shortness of breath. It is an active ingred... | Minor | 0 | [
[
[
218,
23,
209
]
],
[
[
218,
1,
423
],
[
423,
23,
209
]
],
[
[
218,
23,
688
],
[
688,
24,
209
]
],
[
[
218,
1,
423
],
[
423,
40,
... | [
[
[
"Beclomethasone dipropionate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Racepinephrine"
]
],
[
[
"Beclomethasone dipropionate",
"{u} (Compound) resembles {v} (Compound)",
"Ciclesonide"
],
[
"Cicles... | Beclomethasone dipropionate (Compound) resembles Ciclesonide (Compound) and Ciclesonide may cause a minor interaction that can limit clinical effects when taken with Racepinephrine
Beclomethasone dipropionate may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cau... |
DB00092 | DB15965 | 58 | 1,330 | [
"DDInter40",
"DDInter1270"
] | Alefacept | Naxitamab | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
58,
24,
1330
]
],
[
[
58,
23,
1193
],
[
1193,
23,
1330
]
],
[
[
58,
24,
1532
],
[
1532,
24,
1330
]
],
[
[
58,
63,
1184
],
[
1184,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
... | Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosf... |
DB00072 | DB06674 | 550 | 908 | [
"DDInter1846",
"DDInter837"
] | Trastuzumab | Golimumab | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
550,
25,
908
]
],
[
[
550,
24,
200
],
[
200,
63,
908
]
],
[
[
550,
24,
1136
],
[
1136,
24,
908
]
],
[
[
550,
25,
334
],
[
334,
6... | [
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Can... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Denosuma... |
DB00220 | DB00518 | 798 | 510 | [
"DDInter1276",
"DDInter35"
] | Nelfinavir | Albendazole | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Moderate | 1 | [
[
[
798,
24,
510
]
],
[
[
798,
6,
4973
],
[
4973,
45,
510
]
],
[
[
798,
18,
2183
],
[
2183,
46,
510
]
],
[
[
798,
7,
5360
],
[
5360,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albendazole"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Nelfinavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Albendazole (Compound)
Nelfinavir (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is upregulated by Albendazole (Compound)
Nelfinavir (Compound) upregulates PDIA5 (Gene) and PDIA5 (Gene) is upregulated by Albendazole (Compound)
Nelfinavir (Com... |
DB00431 | DB01579 | 1,503 | 341 | [
"DDInter1072",
"DDInter1439"
] | Lindane | Phendimetrazine | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | Moderate | 1 | [
[
[
1503,
24,
341
]
],
[
[
1503,
21,
28762
],
[
28762,
60,
341
]
],
[
[
1503,
24,
401
],
[
401,
24,
341
]
],
[
[
1503,
24,
1662
],
[
1662,... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Lindane",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused ... | Lindane (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Phendimetrazine (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Phendi... |
DB00468 | DB11853 | 1,424 | 230 | [
"DDInter1557",
"DDInter1577"
] | Quinine | Relugolix | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Major | 2 | [
[
[
1424,
25,
230
]
],
[
[
1424,
24,
129
],
[
129,
23,
230
]
],
[
[
1424,
23,
112
],
[
112,
23,
230
]
],
[
[
1424,
63,
1101
],
[
1101,
... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Quinine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidaz... |
DB01611 | DB11986 | 1,487 | 484 | [
"DDInter893",
"DDInter648"
] | Hydroxychloroquine | Entrectinib | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
1487,
25,
484
]
],
[
[
1487,
62,
1247
],
[
1247,
23,
484
]
],
[
[
1487,
63,
112
],
[
112,
23,
484
]
],
[
[
1487,
64,
1539
],
[
1539,
... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00342 | DB09420 | 1,181 | 1,074 | [
"DDInter1770",
"DDInter953"
] | Terfenadine | Iodide I-123 | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
1181,
24,
1074
]
],
[
[
1181,
23,
1247
],
[
1247,
24,
1074
]
],
[
[
1181,
25,
1487
],
[
1487,
24,
1074
]
],
[
[
1181,
24,
401
],
[
401... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Terfenadine may lead to a major life threatening interaction when taken with Hydroxychloroquine and... |
DB11057 | DB14568 | 720 | 982 | [
"DDInter1223",
"DDInter1000"
] | Mineral oil | Ivosidenib | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
720,
24,
982
]
],
[
[
720,
63,
613
],
[
613,
24,
982
]
],
[
[
720,
63,
472
],
[
472,
25,
982
]
],
[
[
720,
24,
124
],
[
124,
25,... | [
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
... | Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Alfuzosin and Alfuz... |
DB00712 | DB15233 | 1,274 | 1,650 | [
"DDInter764",
"DDInter142"
] | Flurbiprofen (ophthalmic) | Avapritinib | Flurbiprofen can cause developmental toxicity and female reproductive toxicity according to state or federal government labeling requirements. | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Moderate | 1 | [
[
[
1274,
37,
1650
]
],
[
[
1274,
24,
1478
],
[
1478,
24,
1650
]
],
[
[
1274,
63,
92
],
[
92,
24,
1650
]
],
[
[
1274,
62,
752
],
[
752,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that ... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib and Flurbiprofen may lead to a major life threatening interaction when taken with Avapritinib
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may ... |
DB00388 | DB01105 | 1,636 | 222 | [
"DDInter1453",
"DDInter1665"
] | Phenylephrine | Sibutramine | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1636,
24,
222
]
],
[
[
1636,
21,
28763
],
[
28763,
60,
222
]
],
[
[
1636,
63,
847
],
[
847,
23,
222
]
],
[
[
1636,
24,
659
],
[
659,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Phenylephrine",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Effect... | Phenylephrine (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Sibutramine (Compound)
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine may cause a minor interaction that can limit clinical effects when taken wit... |
DB01234 | DB11689 | 1,220 | 321 | [
"DDInter513",
"DDInter1659"
] | Dexamethasone | Selumetinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Major | 2 | [
[
[
1220,
25,
321
]
],
[
[
1220,
24,
392
],
[
392,
24,
321
]
],
[
[
1220,
25,
235
],
[
235,
24,
321
]
],
[
[
1220,
24,
1297
],
[
1297,
... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selumetinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapa... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Dexamethasone may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cau... |
DB00619 | DB00744 | 1,419 | 1,288 | [
"DDInter909",
"DDInter1962"
] | Imatinib | Zileuton | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, a... | Moderate | 1 | [
[
[
1419,
24,
1288
]
],
[
[
1419,
6,
8374
],
[
8374,
45,
1288
]
],
[
[
1419,
21,
29232
],
[
29232,
60,
1288
]
],
[
[
1419,
24,
1297
],
[
1... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Imatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zileuton (Compound)
Imatinib (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Zileuton (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat... |
DB01136 | DB01575 | 772 | 1,054 | [
"DDInter305",
"DDInter1005"
] | Carvedilol | Kaolin | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Kaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate. | Minor | 0 | [
[
[
772,
23,
1054
]
],
[
[
772,
24,
407
],
[
407,
63,
1054
]
],
[
[
772,
63,
85
],
[
85,
24,
1054
]
],
[
[
772,
24,
407
],
[
407,
63... | [
[
[
"Carvedilol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Kaolin"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium"... | Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a m... |
DB12500 | DB14723 | 283 | 159 | [
"DDInter714",
"DDInter1026"
] | Fedratinib | Larotrectinib | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
283,
24,
159
]
],
[
[
283,
63,
222
],
[
222,
23,
159
]
],
[
[
283,
62,
907
],
[
907,
23,
159
]
],
[
[
283,
23,
466
],
[
466,
23,... | [
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Dorav... |
DB00673 | DB12095 | 723 | 179 | [
"DDInter112",
"DDInter1760"
] | Aprepitant | Telotristat ethyl | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
723,
24,
179
]
],
[
[
723,
24,
310
],
[
310,
24,
179
]
],
[
[
723,
25,
1493
],
[
1493,
24,
179
]
],
[
[
723,
64,
1425
],
[
1425,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Aprepitant may lead to a major life threatening interaction when taken with Halofantrine and Halofantri... |
DB00694 | DB12332 | 51 | 1,619 | [
"DDInter485",
"DDInter1626"
] | Daunorubicin | Rucaparib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
51,
24,
1619
]
],
[
[
51,
23,
112
],
[
112,
23,
1619
]
],
[
[
51,
24,
259
],
[
259,
24,
1619
]
],
[
[
51,
24,
151
],
[
151,
63,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Daunorubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and R... |
DB00286 | DB11921 | 380 | 1,019 | [
"DDInter439",
"DDInter492"
] | Conjugated estrogens | Deflazacort | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
380,
24,
1019
]
],
[
[
380,
24,
959
],
[
959,
24,
1019
]
],
[
[
380,
40,
890
],
[
890,
24,
1019
]
],
[
[
380,
24,
1385
],
[
1385,
... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipiz... | Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Conjugated estrogens (Compound) resembles Mestranol (Compound) and Mestranol may cause a moderate inter... |
DB00726 | DB00771 | 1,164 | 262 | [
"DDInter1876",
"DDInter397"
] | Trimipramine | Clidinium | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Moderate | 1 | [
[
[
1164,
24,
262
]
],
[
[
1164,
24,
1511
],
[
1511,
63,
262
]
],
[
[
1164,
63,
19
],
[
19,
24,
262
]
],
[
[
1164,
1,
508
],
[
508,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and ... |
DB00653 | DB11943 | 544 | 255 | [
"DDInter1120",
"DDInter495"
] | Magnesium sulfate | Delafloxacin | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Moderate | 1 | [
[
[
544,
24,
255
]
],
[
[
544,
24,
613
],
[
613,
23,
255
]
],
[
[
544,
24,
1283
],
[
1283,
24,
255
]
],
[
[
544,
24,
1473
],
[
1473,
... | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesi... |
DB00224 | DB11691 | 215 | 1,499 | [
"DDInter917",
"DDInter1258"
] | Indinavir | Naldemedine | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
215,
24,
1499
]
],
[
[
215,
24,
723
],
[
723,
24,
1499
]
],
[
[
215,
40,
798
],
[
798,
24,
1499
]
],
[
[
215,
25,
1670
],
[
1670,
... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Indinavir (Compound) resembles Nelfinavir (Compound) and Nelfinavir may cause a moderate interaction that could ... |
DB00388 | DB00907 | 1,636 | 290 | [
"DDInter1453",
"DDInter427"
] | Phenylephrine | Cocaine (topical) | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Major | 2 | [
[
[
1636,
25,
290
]
],
[
[
1636,
24,
85
],
[
85,
1,
290
]
],
[
[
1636,
21,
28741
],
[
28741,
60,
290
]
],
[
[
1636,
24,
455
],
[
455,
... | [
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine"... | Phenylephrine may lead to a major life threatening interaction when taken with Cocaine
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Cocaine (Compound)
Phenylephrine (Compound) causes Agitation (Side Effect) and Agitation (Side E... |
DB00860 | DB11601 | 891 | 1,270 | [
"DDInter1513",
"DDInter1889"
] | Prednisolone | Tuberculin purified protein derivative | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
891,
24,
1270
]
],
[
[
891,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
891,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
891,
1,
1486
],
[
1486,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Prednisolone may lead to a major life threatening interaction when taken with Cl... |
DB00011 | DB05528 | 1,451 | 1,070 | [
"DDInter944",
"DDInter1228"
] | Interferon alfa-n1 | Mipomersen | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
1451,
25,
1070
]
],
[
[
1451,
24,
14
],
[
14,
25,
1070
]
],
[
[
1451,
24,
350
],
[
350,
64,
1070
]
],
[
[
1451,
25,
593
],
[
593,
... | [
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may lead to a major life threatening interaction when taken with Mipomersen
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and ... |
DB00398 | DB01236 | 79 | 679 | [
"DDInter1702",
"DDInter1664"
] | Sorafenib | Sevoflurane | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Moderate | 1 | [
[
[
79,
24,
679
]
],
[
[
79,
24,
1262
],
[
1262,
40,
679
]
],
[
[
79,
6,
8374
],
[
8374,
45,
679
]
],
[
[
79,
21,
29232
],
[
29232,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Sorafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sevoflurane (Compound)
Sorafenib (Compound) causes Urticaria (Side Effect) and Urticaria ... |
DB00960 | DB11093 | 887 | 636 | [
"DDInter1471",
"DDInter273"
] | Pindolol | Calcium citrate | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
887,
24,
636
]
],
[
[
887,
1,
819
],
[
819,
24,
636
]
],
[
[
887,
62,
542
],
[
542,
24,
636
]
],
[
[
887,
40,
1121
],
[
1121,
24... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a modera... | Pindolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Pindolol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that ... |
DB00289 | DB00631 | 847 | 372 | [
"DDInter132",
"DDInter405"
] | Atomoxetine | Clofarabine | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
847,
24,
372
]
],
[
[
847,
21,
29122
],
[
29122,
60,
372
]
],
[
[
847,
24,
927
],
[
927,
63,
372
]
],
[
[
847,
63,
1560
],
[
1560,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Atomoxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"... | Atomoxetine (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Clofarabine (Compound)
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate disea... |
DB00359 | DB00553 | 161 | 92 | [
"DDInter1721",
"DDInter1177"
] | Sulfadiazine | Methoxsalen | One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Moderate | 1 | [
[
[
161,
24,
92
]
],
[
[
161,
6,
8374
],
[
8374,
45,
92
]
],
[
[
161,
21,
28640
],
[
28640,
60,
92
]
],
[
[
161,
1,
1247
],
[
1247,
... | [
[
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxsalen"
]
],
[
[
"Sulfadiazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Sulfadiazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Methoxsalen (Compound)
Sulfadiazine (Compound) causes Depression (Side Effect) and Depression (Side Effect) is caused by Methoxsalen (Compound)
Sulfadiazine (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a moderat... |
DB00468 | DB01236 | 1,424 | 679 | [
"DDInter1557",
"DDInter1664"
] | Quinine | Sevoflurane | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Moderate | 1 | [
[
[
1424,
24,
679
]
],
[
[
1424,
24,
1262
],
[
1262,
40,
679
]
],
[
[
1424,
6,
6365
],
[
6365,
45,
679
]
],
[
[
1424,
21,
28862
],
[
28862... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[
"... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Quinine (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Sevoflurane (Compound)
Quinine (Compound) causes Ventricular tachycardia (Side Effect) and Ve... |
DB01097 | DB15965 | 1,377 | 1,330 | [
"DDInter1033",
"DDInter1270"
] | Leflunomide | Naxitamab | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Major | 2 | [
[
[
1377,
25,
1330
]
],
[
[
1377,
23,
1193
],
[
1193,
23,
1330
]
],
[
[
1377,
25,
1532
],
[
1532,
24,
1330
]
],
[
[
1377,
63,
10
],
[
10,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naxitamab"
]
],
[
[
"Leflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gl... | Leflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Leflunomide may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may c... |
DB00581 | DB01128 | 355 | 918 | [
"DDInter1018",
"DDInter204"
] | Lactulose | Bicalutamide | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Moderate | 1 | [
[
[
355,
24,
918
]
],
[
[
355,
24,
129
],
[
129,
40,
918
]
],
[
[
355,
21,
29134
],
[
29134,
60,
918
]
],
[
[
355,
24,
786
],
[
786,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Lactulose (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Bicalutamide (Compound)
Lactulose may cause a moderate inter... |
DB00366 | DB00843 | 1,594 | 479 | [
"DDInter600",
"DDInter583"
] | Doxylamine | Donepezil | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Moderate | 1 | [
[
[
1594,
24,
479
]
],
[
[
1594,
24,
843
],
[
843,
1,
479
]
],
[
[
1594,
21,
28741
],
[
28741,
60,
479
]
],
[
[
1594,
24,
1442
],
[
1442,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine and Tetrabenazine (Compound) resembles Donepezil (Compound)
Doxylamine (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Donepezil (Compound)
Doxylamine may cause a moderate interact... |
DB01394 | DB11988 | 1,554 | 270 | [
"DDInter431",
"DDInter1321"
] | Colchicine | Ocrelizumab | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
1554,
24,
270
]
],
[
[
1554,
63,
134
],
[
134,
24,
270
]
],
[
[
1554,
25,
1491
],
[
1491,
24,
270
]
],
[
[
1554,
24,
951
],
[
951,
... | [
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
... | Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Colchicine may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may c... |
DB00087 | DB11003 | 599 | 748 | [
"DDInter41",
"DDInter100"
] | Alemtuzumab | Anthrax vaccine | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
599,
24,
748
]
],
[
[
599,
24,
322
],
[
322,
24,
748
]
],
[
[
599,
24,
564
],
[
564,
63,
748
]
],
[
[
599,
25,
676
],
[
676,
63,... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib an... |
DB01114 | DB13913 | 272 | 1,536 | [
"DDInter362",
"DDInter175"
] | Chlorpheniramine | Belladonna | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Belladonna, also known as atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family _Solanaceae_. Its roots, leaves and fruits contain , , and mostly, . These alkaloids are naturally-occurring muscarinic antagonists. is a non-selective muscarinic antagonist that is mainly used as ... | Moderate | 1 | [
[
[
272,
24,
1536
]
],
[
[
272,
24,
849
],
[
849,
24,
1536
]
],
[
[
272,
63,
128
],
[
128,
24,
1536
]
],
[
[
272,
74,
1376
],
[
1376,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dexbromph... |
DB01182 | DB09330 | 371 | 985 | [
"DDInter1534",
"DDInter1352"
] | Propafenone | Osimertinib | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
371,
25,
985
]
],
[
[
371,
62,
112
],
[
112,
23,
985
]
],
[
[
371,
63,
480
],
[
480,
24,
985
]
],
[
[
371,
24,
119
],
[
119,
63,... | [
[
[
"Propafenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Propafenone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Propafenone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and F... |
DB04861 | DB09134 | 1,592 | 1,552 | [
"DDInter1271",
"DDInter966"
] | Nebivolol | Ioversol | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Moderate | 1 | [
[
[
1592,
24,
1552
]
],
[
[
1592,
63,
1648
],
[
1648,
24,
1552
]
],
[
[
1592,
24,
278
],
[
278,
63,
1552
]
],
[
[
1592,
24,
512
],
[
512,
... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodi... |
DB00065 | DB00708 | 581 | 1,454 | [
"DDInter923",
"DDInter1718"
] | Infliximab | Sufentanil | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Moderate | 1 | [
[
[
581,
24,
1454
]
],
[
[
581,
24,
704
],
[
704,
40,
1454
]
],
[
[
581,
25,
1093
],
[
1093,
63,
1454
]
],
[
[
581,
25,
1101
],
[
1101,
... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sufentanil"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Sufentanil (Compound)
Infliximab may lead to a major life threatening interaction when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate disease... |
DB00448 | DB09263 | 1,215 | 1,436 | [
"DDInter1022",
"DDInter1399"
] | Lansoprazole | Patiromer | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patirome... | Moderate | 1 | [
[
[
1215,
24,
1436
]
],
[
[
1215,
40,
660
],
[
660,
24,
1436
]
],
[
[
1215,
24,
428
],
[
428,
63,
1436
]
],
[
[
1215,
63,
1152
],
[
1152,
... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a ... | Lansoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate int... |
DB00910 | DB06410 | 1,041 | 1,196 | [
"DDInter1394",
"DDInter595"
] | Paricalcitol | Doxercalciferol | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | Major | 2 | [
[
[
1041,
25,
1196
]
],
[
[
1041,
63,
359
],
[
359,
24,
1196
]
],
[
[
1041,
24,
463
],
[
463,
24,
1196
]
],
[
[
1041,
24,
1339
],
[
1339,
... | [
[
[
"Paricalcitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
],
[
... | Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Rifa... |
DB00673 | DB09074 | 723 | 1,362 | [
"DDInter112",
"DDInter1327"
] | Aprepitant | Olaparib | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Major | 2 | [
[
[
723,
25,
1362
]
],
[
[
723,
24,
627
],
[
627,
63,
1362
]
],
[
[
723,
24,
896
],
[
896,
24,
1362
]
],
[
[
723,
63,
576
],
[
576,
... | [
[
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
],
[
"Bictegravir... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir and Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposi... |
DB04868 | DB10795 | 478 | 221 | [
"DDInter1293",
"DDInter1486"
] | Nilotinib | Poliovirus type 1 antigen (formaldehyde inactivated) | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
478,
24,
221
]
],
[
[
478,
25,
36
],
[
36,
24,
221
]
],
[
[
478,
64,
581
],
[
581,
24,
221
]
],
[
[
478,
63,
599
],
[
599,
24,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Er... | Nilotinib may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Nilotinib may lead to a major life threatening interaction when taken with Infliximab and ... |
DB09030 | DB10344 | 840 | 992 | [
"DDInter1945",
"DDInter818"
] | Vorapaxar | Ginger | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Ginger allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
840,
24,
992
]
],
[
[
840,
64,
1578
],
[
1578,
24,
992
]
],
[
[
840,
25,
1421
],
[
1421,
63,
992
]
],
[
[
840,
25,
498
],
[
498,
... | [
[
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
... | Vorapaxar may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Vorapaxar may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction ... |
DB00030 | DB01319 | 1,685 | 34 | [
"DDInter934",
"DDInter777"
] | Insulin human | Fosamprenavir | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
1685,
24,
34
]
],
[
[
1685,
24,
1091
],
[
1091,
40,
34
]
],
[
[
1685,
24,
609
],
[
609,
23,
34
]
],
[
[
1685,
24,
245
],
[
245,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interact... |
DB00662 | DB00726 | 717 | 1,164 | [
"DDInter1873",
"DDInter1876"
] | Trimethobenzamide | Trimipramine | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Moderate | 1 | [
[
[
717,
24,
1164
]
],
[
[
717,
24,
1237
],
[
1237,
40,
1164
]
],
[
[
717,
63,
508
],
[
508,
40,
1164
]
],
[
[
717,
64,
675
],
[
675,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramin... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Trim... |
DB00341 | DB09034 | 1,242 | 1,313 | [
"DDInter343",
"DDInter1733"
] | Cetirizine | Suvorexant | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
1242,
24,
1313
]
],
[
[
1242,
24,
649
],
[
649,
24,
1313
]
],
[
[
1242,
74,
701
],
[
701,
24,
1313
]
],
[
[
1242,
24,
407
],
[
407,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Cetirizine (Compound) resembles Clemastine (Compound) and Cetirizine may cause a moderate interaction that could... |
DB04868 | DB14444 | 478 | 151 | [
"DDInter1293",
"DDInter924"
] | Nilotinib | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
478,
24,
151
]
],
[
[
478,
63,
66
],
[
66,
24,
151
]
],
[
[
478,
25,
1619
],
[
1619,
24,
151
]
],
[
[
478,
24,
850
],
[
850,
24,... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exa... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Nilotinib may lead to a major life thr... |
DB09046 | DB11979 | 1,094 | 1,320 | [
"DDInter1201",
"DDInter625"
] | Metreleptin | Elagolix | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1094,
24,
1320
]
],
[
[
1094,
62,
168
],
[
168,
23,
1320
]
],
[
[
1094,
23,
1612
],
[
1612,
23,
1320
]
],
[
[
1094,
24,
1297
],
[
1297... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Metreleptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Metreleptin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Metreleptin may cause a minor interaction that can limit clinical effects when taken with Fostemsavir and Fostemsavir... |
DB00460 | DB08881 | 612 | 868 | [
"DDInter1929",
"DDInter1925"
] | Verteporfin | Vemurafenib | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
612,
24,
868
]
],
[
[
612,
21,
28847
],
[
28847,
60,
868
]
],
[
[
612,
24,
578
],
[
578,
24,
868
]
],
[
[
612,
24,
1040
],
[
1040,
... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Verteporfin",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect... | Verteporfin (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB10583 | DB11793 | 949 | 738 | [
"DDInter415",
"DDInter1297"
] | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Niraparib | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
949,
24,
738
]
],
[
[
949,
63,
1213
],
[
1213,
24,
738
]
],
[
[
949,
24,
1619
],
[
1619,
63,
738
]
],
[
[
949,
24,
351
],
[
351,
... | [
[
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate ... | Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Clostridium tetani toxoid antigen (formaldehyde inactivated) may ... |
DB00054 | DB05773 | 1,432 | 1,047 | [
"DDInter6",
"DDInter1848"
] | Abciximab | Trastuzumab emtansine | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Major | 2 | [
[
[
1432,
25,
1047
]
],
[
[
1432,
24,
848
],
[
848,
24,
1047
]
],
[
[
1432,
24,
643
],
[
643,
63,
1047
]
],
[
[
1432,
25,
1018
],
[
1018,
... | [
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ib... | Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine... |
DB00211 | DB00397 | 1,290 | 1,466 | [
"DDInter1213",
"DDInter1458"
] | Midodrine | Phenylpropanolamine | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Moderate | 1 | [
[
[
1290,
24,
1466
]
],
[
[
1290,
63,
73
],
[
73,
25,
1466
]
],
[
[
1290,
6,
5214
],
[
5214,
45,
1466
]
],
[
[
1290,
21,
28717
],
[
28717,... | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
... | Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Phenylpropanolamine
Midodrine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Phenylpropanolamine (Compound)
Midodrine (Comp... |
DB00358 | DB01263 | 1,010 | 859 | [
"DDInter1140",
"DDInter1494"
] | Mefloquine | Posaconazole | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
1010,
24,
859
]
],
[
[
1010,
6,
4973
],
[
4973,
45,
859
]
],
[
[
1010,
21,
28762
],
[
28762,
60,
859
]
],
[
[
1010,
23,
112
],
[
112,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Mefloquine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound)
Mefloquine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Met... |
DB00196 | DB09078 | 600 | 1,228 | [
"DDInter743",
"DDInter1036"
] | Fluconazole | Lenvatinib | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
600,
24,
1228
]
],
[
[
600,
23,
112
],
[
112,
23,
1228
]
],
[
[
600,
25,
463
],
[
463,
23,
1228
]
],
[
[
600,
24,
1100
],
[
1100,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Fluconazole may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin may ca... |
DB01259 | DB08893 | 392 | 271 | [
"DDInter1024",
"DDInter1229"
] | Lapatinib | Mirabegron | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Minor | 0 | [
[
[
392,
23,
271
]
],
[
[
392,
63,
371
],
[
371,
40,
271
]
],
[
[
392,
6,
4973
],
[
4973,
45,
271
]
],
[
[
392,
21,
28956
],
[
28956,
... | [
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
],
[
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Propafenone and Propafenone (Compound) resembles Mirabegron (Compound)
Lapatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mirabegron (Compound)
Lapatinib (Compound) causes Palpitations (Side Effect) and Palpitati... |
DB00346 | DB09082 | 472 | 659 | [
"DDInter44",
"DDInter1934"
] | Alfuzosin | Vilanterol | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
472,
24,
659
]
],
[
[
472,
24,
927
],
[
927,
63,
659
]
],
[
[
472,
25,
1069
],
[
1069,
24,
659
]
],
[
[
472,
24,
1450
],
[
1450,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Alfuzosin may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause ... |
DB00619 | DB08930 | 1,419 | 1,459 | [
"DDInter909",
"DDInter582"
] | Imatinib | Dolutegravir | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Minor | 0 | [
[
[
1419,
23,
1459
]
],
[
[
1419,
21,
28698
],
[
28698,
60,
1459
]
],
[
[
1419,
63,
353
],
[
353,
23,
1459
]
],
[
[
1419,
35,
478
],
[
478... | [
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolutegravir"
]
],
[
[
"Imatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by ... | Imatinib (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Dolutegravir (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Dolutegra... |
DB00834 | DB00982 | 932 | 1,517 | [
"DDInter1215",
"DDInter991"
] | Mifepristone | Isotretinoin | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Moderate | 1 | [
[
[
932,
24,
1517
]
],
[
[
932,
7,
2884
],
[
2884,
46,
1517
]
],
[
[
932,
18,
3887
],
[
3887,
46,
1517
]
],
[
[
932,
18,
3965
],
[
3965,
... | [
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
],
[
[
"Mifepristone",
"{u} (Compound) upregulates {v} (Gene)",
"ECH1"
],
[
"ECH1",
"{u} (Gene) is upregulated by {v... | Mifepristone (Compound) upregulates ECH1 (Gene) and ECH1 (Gene) is upregulated by Isotretinoin (Compound)
Mifepristone (Compound) downregulates PRSS23 (Gene) and PRSS23 (Gene) is upregulated by Isotretinoin (Compound)
Mifepristone (Compound) downregulates MRPS2 (Gene) and MRPS2 (Gene) is downregulated by Isotretinoin (... |
DB00353 | DB14568 | 588 | 982 | [
"DDInter1187",
"DDInter1000"
] | Methylergometrine | Ivosidenib | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
588,
24,
982
]
],
[
[
588,
63,
1101
],
[
1101,
23,
982
]
],
[
[
588,
40,
628
],
[
628,
24,
982
]
],
[
[
588,
24,
1478
],
[
1478,
... | [
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
... | Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Methylergometrine (Compound) resembles Ergometrine (Compound) and Ergometrine may cause a moderate interact... |
DB00323 | DB00835 | 1,062 | 100 | [
"DDInter1829",
"DDInter245"
] | Tolcapone | Brompheniramine | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
1062,
24,
100
]
],
[
[
1062,
24,
832
],
[
832,
24,
100
]
],
[
[
1062,
24,
649
],
[
649,
63,
100
]
],
[
[
1062,
6,
6017
],
[
6017,
... | [
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
... | Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol... |
DB00515 | DB14509 | 589 | 1,399 | [
"DDInter387",
"DDInter1081"
] | Cisplatin | Lithium carbonate | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Minor | 0 | [
[
[
589,
23,
1399
]
],
[
[
589,
24,
1555
],
[
1555,
24,
1399
]
],
[
[
589,
63,
322
],
[
322,
24,
1399
]
],
[
[
589,
25,
770
],
[
770,
... | [
[
[
"Cisplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and... |
DB01211 | DB01242 | 609 | 1,237 | [
"DDInter393",
"DDInter410"
] | Clarithromycin | Clomipramine | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
609,
24,
1237
]
],
[
[
609,
64,
684
],
[
684,
1,
1237
]
],
[
[
609,
63,
1164
],
[
1164,
1,
1237
]
],
[
[
609,
63,
902
],
[
902,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
... | Clarithromycin may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Clomipramine (Compo... |
DB01176 | DB01186 | 537 | 107 | [
"DDInter453",
"DDInter1430"
] | Cyclizine | Pergolide | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic tr... | Moderate | 1 | [
[
[
537,
24,
107
]
],
[
[
537,
21,
28898
],
[
28898,
60,
107
]
],
[
[
537,
63,
1594
],
[
1594,
24,
107
]
],
[
[
537,
24,
849
],
[
849,
... | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Cyclizine",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is c... | Cyclizine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Pergolide (Compound)
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Perg... |
DB01166 | DB13179 | 477 | 68 | [
"DDInter379",
"DDInter1882"
] | Cilostazol | Troleandomycin | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | A macrolide antibiotic that is similar to erythromycin. | Major | 2 | [
[
[
477,
25,
68
]
],
[
[
477,
24,
1374
],
[
1374,
23,
68
]
],
[
[
477,
63,
222
],
[
222,
23,
68
]
],
[
[
477,
24,
1662
],
[
1662,
24... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abira... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and S... |
DB00853 | DB11601 | 1,686 | 1,270 | [
"DDInter1762",
"DDInter1889"
] | Temozolomide | Tuberculin purified protein derivative | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1686,
24,
1270
]
],
[
[
1686,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
1686,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
1686,
63,
1555
],
[
15... | [
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Temozolomide may lead to a major life threatening interaction when taken with Cl... |
DB08875 | DB14840 | 1,618 | 861 | [
"DDInter262",
"DDInter1601"
] | Cabozantinib | Ripretinib | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
1618,
24,
861
]
],
[
[
1618,
25,
351
],
[
351,
24,
861
]
],
[
[
1618,
24,
214
],
[
214,
24,
861
]
],
[
[
1618,
63,
353
],
[
353,
... | [
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Riboci... | Cabozantinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib ma... |
DB00004 | DB04865 | 669 | 4 | [
"DDInter499",
"DDInter1335"
] | Denileukin diftitox | Omacetaxine mepesuccinate | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
669,
24,
4
]
],
[
[
669,
25,
770
],
[
770,
24,
4
]
],
[
[
669,
24,
496
],
[
496,
63,
4
]
],
[
[
669,
24,
66
],
[
66,
24,
4... | [
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Denileukin diftitox",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomi... | Denileukin diftitox may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with H... |
DB00445 | DB01224 | 322 | 623 | [
"DDInter655",
"DDInter1553"
] | Epirubicin | Quetiapine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
322,
24,
623
]
],
[
[
322,
24,
827
],
[
827,
1,
623
]
],
[
[
322,
64,
695
],
[
695,
1,
623
]
],
[
[
322,
63,
508
],
[
508,
1,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Epirubicin may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound)
Epirubicin may caus... |
DB00601 | DB06372 | 453 | 259 | [
"DDInter1073",
"DDInter1594"
] | Linezolid | Rilonacept | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
453,
24,
259
]
],
[
[
453,
24,
270
],
[
270,
63,
259
]
],
[
[
453,
24,
309
],
[
309,
24,
259
]
],
[
[
453,
63,
168
],
[
168,
24,... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
... | Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabe... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.